Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
144.00    -1.00 (-0.69%)
Bid:
144.00
Ask:
145.00
Spread: 1.00 (0.694%)
Market Cap: £113.00m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Systems integration partner

13 May 2005 07:01

Xaar PLC13 May 2005 FOR IMMEDIATE RELEASE 13 May 2005 Xaar plc IMPIKA APPOINTED AS SYSTEMS INTEGRATION PARTNER Xaar plc ("Xaar"), the inkjet printing technology group headquartered inCambridge, and IMPIKA SA ("IMPIKA") of Aubagne, France are pleased to announce ajoint agreement for the provision of integration services for Xaar printheadsand other products. Under the agreement both parties will co-operate to provide complete turnkeysolutions for clients wishing to use Xaar technology for their productionprocesses, to open up new applications and create bespoke solutions. IMPIKA haslong experience with inkjet, including its application to the printing ofplastic and smart cards, packaging, labelling as well as special applicationsfor printing on CDs, glass and metal. Impika is also developing solutions basedon its material jetting technology for microelectronics and biomedicalapplications. Nigel Berry, Deputy CEO of Xaar commented: "I am very pleased to announce thisrelationship with IMPIKA. We previously stated our intention to partner with asmall number of high quality integrators which can offer existing and potentialusers of our technology a complete package of integration skills and bespokeequipment. We have known the team at IMPIKA for some time now and have beenimpressed by their standards and innovation. I look forward to working withthem on future projects." Paul Morgavi, IMPIKA'S CEO said: "Xaar is a great partner for us and we arealready forming strong links with their technical and marketing teams. There isa clear synergy between Xaar and Impika with both parties introducing newmarkets into the joint relationship. Last year we introduced our C9000 productbased on Xaar's Leopard printhead and we are working on various projects foradapting our IPS print engine to the next generation of Xaar printheads, likethe Omnidot and HSS. Full commercial release of these products is anticipatedlater this year or early next year." About Xaar Xaar plc is a market-leading inkjet technology company. It targets the world'sindustrial, commercial and office printing markets. The industrial andcommercial printing markets are targeted by Xaar's own range of inkjet productsin conjunction with partners and other key players in those markets; the officeprinting market is approached through Xaar's strong list of licensees.Additional information about Xaar is available at www.xaar.co.uk. About IMPIKA: Created in March 2003 as a spin-out from Gemplus, IMPIKA is headquartered atAubagne in the south of France. IMPIKA offers high-performance industrialprinting and material jetting solutions using inkjet technology; it currentlyhas 37 employees. IMPIKA designs, develops, implements and markets hardware and softwaresolutions, as well as the required engineering as regards ink and materialjetting, for industrial applications including digital printing,microelectronics and biotechnologies. Additional information about IMPIKA isavailable at www.impika.com. Contacts Xaar plc: 01223-423663Ian Dinwoodie, Chief Executive www.xaar.co.ukNigel Berry, Group Finance Director & Deputy Chief Executive IMPIKA: +33 (0)4 42 62 43 00Paul Morgavi, CEO www.impika.com Bankside Consultants:Steve Liebmann 020-7444-4163 /07802-888159 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
3rd Feb 20254:15 pmRNSTotal Voting Rights
22nd Jan 202512:30 pmRNSBlock listing Interim Review
21st Jan 20253:00 pmRNSHolding(s) in Company
15th Jan 20257:00 amRNSTrading update & notification of full year results
15th Jan 20257:00 amRNSAppointment of Chief Financial Officer
11th Dec 202410:30 amRNS2024 Full Year Trading Update
4th Dec 202410:45 amRNSUpdate statement on 2024 AGM voting results
3rd Dec 202410:50 amRNSTotal Voting Rights
20th Nov 20247:00 amRNSBoard changes
1st Nov 202412:00 pmRNSTotal Voting Rights
1st Oct 202411:30 amRNSTotal Voting Rights
18th Sep 20247:00 amRNSInterim Results
2nd Sep 20241:45 pmRNSTotal Voting Rights
2nd Aug 20242:30 pmRNSHolding(s) in Company
1st Aug 202411:15 amRNSTotal Voting Rights
30th Jul 20247:00 amRNSNOTICE OF RESULTS AND UPDATE ON TRADING
3rd Jul 202411:45 amRNSBlock listing Interim Review
2nd Jul 20242:00 pmRNSTotal Voting Rights
28th Jun 202410:00 amRNSDirector Declaration
3rd Jun 20242:45 pmRNSTotal Voting Rights
30th May 202412:00 pmRNSBoard changes
29th May 20241:45 pmRNSResult of AGM
29th May 20249:30 amRNSHolding(s) in Company
21st May 20249:30 amRNSDirector/PDMR Shareholding
20th May 20244:30 pmRNSDirector/PDMR Shareholding
13th May 20249:42 amRNSHolding(s) in Company
1st May 20244:15 pmRNSTotal Voting Rights
30th Apr 20244:30 pmRNSDirector/PDMR Shareholding
22nd Apr 202410:51 amRNSAnnual Financial Report
2nd Apr 202412:00 pmRNSTotal Voting Rights
1st Mar 202410:15 amRNSTotal Voting Rights
26th Feb 20249:00 amRNSHolding(s) in Company
23rd Feb 202410:30 amRNSBoard Change
1st Feb 20241:32 pmRNSTotal Voting Rights
29th Jan 202412:04 pmRNSHolding(s) in Company
12th Jan 20243:15 pmRNSBlock listing Interim Review
12th Jan 20247:00 amRNSNotification of Results & Full year Guidance
8th Jan 202412:36 pmRNSTotal Voting Rights
12th Dec 20239:00 amRNSNotification of Transactions of Directors & PDMRs
11th Dec 20233:00 pmRNSNotification of Transactions of Directors & PDMRs
1st Dec 202311:00 amRNSTotal Voting Rights
1st Dec 202310:00 amRNSDirector Declaration
29th Nov 20237:00 amRNSTrading Update
17th Nov 20234:07 pmRNSHolding(s) in Company
9th Nov 20231:53 pmRNSDirector/PDMR Shareholding
3rd Nov 202310:52 amRNSHolding(s) in Company
1st Nov 20234:03 pmRNSTotal Voting Rights
30th Oct 20237:00 amRNSBoard Changes
2nd Oct 202311:45 amRNSTotal Voting Rights
21st Sep 20233:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.